Drug combo reverses coronary plaques to lowest levels yet

World-first results: Researchers have found a drug combination that reduces coronary atherosclerosis more effectively than statins alone In an Australian-led multicenter, double-blind, placebo-controlled, randomised clinical trial, researchers have discovered that a cholesterol-lowering PCSK9 inhibitor called evolocumab could be key in reducing coronary plaque build-up. The GLAGOV trial was conducted at 197 academic and community hospitals across